This disclosure provides an E. coli strain, which lacks thioredoxin reductase activity encoded by trxB and thioredoxin 1 activity encoded by trxA, and glutathione reductase activity encoded by gor. Said E. coli strain expresses a mutated AhpC protein having glutathione reductase activity and a cytosolic prokaryotic disulfide isomerase. The E. coli strain has an oxidative cytosol and can be used to efficiently produce proteins having disulfide bonds.

Seminaphthofluorophore-selenium probes are disclosed. The probes include a seminaphthofluorophore scaffold substituted with at least one diselenide moiety having a formula —Y—C(Q)O—(CH.sub.2).sub.m—Se—Se—(CH.sub.2).sub.n—OR.sup.f, where R.sup.f is hydrogen or C.sub.1-C.sub.3 alkyl, Q is O or S, Y is O or N(R.sup.g) where R.sup.g is H or alkyl, and m and n independently are integers. The probes may be used to detect presence of a thioredoxin reductase.

An enzyme for reducing cystine to cysteine is a fusion protein that includes the protein activities of thioredoxin (protein i) having KEGG database number EC 1.8.4.8 or EC 1.8.4.10 and thioredoxin reductase (protein ii) having KEGG database number EC 1.8.1.9. The thioredoxin (protein i) is the protein activity of thioredoxin 1 from E. coli and the thioredoxin reductase (protein ii) is the protein activity of the thioredoxin reductase from E. coli. The activity of the fusion protein is at least 100% of the activity of a mixture of the same but unfused individual proteins i and ii. The fusion protein has the enzyme activity to reduce cystine to cysteine. The coding sequences (cds) responsible for the activity of protein i and ii has been fused.

An allergen inactivation method includes an inactivation step of inactivating an allergen present in a reaction system by reduction via a reduced redox protein, and a reduction process of reducing an oxidized redox protein produced by oxidation of the reduced redox protein in the inactivating to the reduced redox protein by donating an electron from an electrode connected to an external power supply outside the reaction system to the oxidized redox protein.

The present invention relates to a novel thermophile-derived keratinase having keratin decomposition ability. Further, the present invention relates to a polynucleotide encoding the keratinase, a recombinant vector containing the same, host cells transformed by using the recombinant vector, and a method for preparing a keratinase including a step of culturing the host cells. Further, the present invention relates to a composition for decomposing keratin containing the enzyme; and a method for decomposing keratin by using the same. Further, the present invention relates to a keratin decomposed product decomposed by the enzyme.

The keratinase according to the present invention rapidly and effectively decomposes hardly-decomposable keratin, and thus it is expected that the keratinase can be used for the effective treatment and the high value-added resource recovery of agricultural and livestock waste, which causes environmental problems (for example, a novel material for enzyme cosmetics), and can be used in an innovative enzymatic bioconversion technique utilizing various decomposition enzyme groups.

The present disclosure relates generally to compositions and methods for the treatment of a RAS-mutant cancer. In particular, the present technology relates to administering a therapeutically effective amount of one or more TXNRD1 inhibitors to a subject diagnosed with, or at risk for a RAS-mutant cancer (e.g., RAS-mutant pancreatic cancer).

The invention concerns Flavine adenine dinucleotide (FAD) for use in preventing and/or treating cancer. The FAD is favorably encapsulated at least partially in a particle with a vector to improve its absorption and distribution while limiting its destruction, in particular by blood hydrolases. The invention relates to the pharmaceutical field and more specifically to oncology or cancerology.

This disclosure provides an E. coli strain, which lacks thioredoxin reductase activity encoded by trxB and thioredoxin 1 activity encoded by trxA, and glutathione reductase activity encoded by gor. Said E. coli strain expresses a mutated AhpC protein having glutathione reductase activity and a cytosolic prokaryotic disulfide isomerase. The E. coli strain has an oxidative cytosol and can be used to efficiently produce proteins having disulfide bonds.

Provided herein are recombinantly engineered polypeptides capable of recycling noncanonical cofactors, and uses thereof. Further provided herein, is a universal growth selection process that can be used to identify said recombinantly engineered polypeptides.

Described herein are methods and compositions for the use of treating damage induced by SD. Aspects of the invention relate to administering to a subject in need thereof an agent that reduces reactive oxygen species. In some embodiments, administration of an agent that reduces reactive oxygen species repairs SD-induced damage in the gut.